Novo Nordisk's Wegovy Gets UK Approval for Higher Dose in Obesity Treatment

Novo Nordisk's stock rose 3% after the UK approved a higher 7.2mg weekly dose of its weight-loss medicine Wegovy for individuals with a BMI of 30 kg/m² or greater. Patients can now receive three 2.4mg injections on the same day each week, along with a diet and exercise regimen. The approval shows regulators' growing backing for GLP-1-based treatments like Wegovy and Ozempic, pushing Novo Nordisk's market value to all-time highs.